Global
Vaccine Conjugates Market Overview
Conjugate vaccines are developed through a covalent bond between a
weak antigen and a strong antigen. This boosts the immune response of the host
towards various diseases. Conjugate vaccines are germ specific and are capable
of identifying just the targeted germs and bacteria, making them usable as a
preventive measure to provide additional protection.
The global vaccine conjugates market is anticipated to register a
14.5% CAGR over the forecast period of 2018-2027. Various factors attributable
to such growth include a rising occurrence of diseases caused by various
microorganisms and bacteria. Further, a mounting awareness towards the
prevention and avoidance of infectious diseases is driving the global vaccine
conjugates market to a great extent. An increasing number of regulatory
approvals to a rising number of vaccines is expected to ascend the global
vaccine conjugates market by 2027.
However, complex manufacturing procedures and low accessibility of
vaccines to rural and remote areas are anticipated to hinder growth in the
global vaccine conjugates market. Moreover, recent incidents of fraud and
malpractice of top vaccine manufacturers are assessed to refrain the market
from augmenting during the forecast period. For instance, in July 2018, a
Chinese vaccine manufacturer was found guilty of fabricating its manufacturing
records and faced legal consequences.
Market Segmentation
The global pneumococcal
vaccine market size is studied by Market Research Future (MRFR) for
various segments. This segmentation is carried out by type, disease indication,
patient stage, pathogen type, end-user, and region. Based on type, the vaccine
conjugates market is segmented into multivalent conjugate vaccines and
monovalent conjugate vaccines. On the basis of disease indication, the vaccine conjugates
market is segmented into influenza, DTP, pneumococcal, and meningococcal. Based
on pathogen type, the vaccine conjugates market is segmented into bacterial
conjugate vaccine, viral conjugate vaccine, and combination conjugate vaccine.
Based on patient stage, the vaccine conjugates market is segmented into adults
conjugate vaccine and pediatrics conjugate vaccine. Based on end-user, the
vaccine conjugates market has been segmented into academic institutes, research
institutes, and pharmaceutical industries.
Detailed Regional Analysis
The global vaccine conjugates market is segmented into the regions
of the Americas, Europe, Asia Pacific, and the Middle East and Africa. Among
these regions, the Americas are expected to spearhead the global vaccine conjugates
market during the forecast period. This market command can be accredited to the
rising prevalence of infectious diseases and increasing awareness of
vaccination. Further, technological advancements and rising government
initiatives towards the encouragement of vaccination programs are contributing
to the heavy ascension of the vaccine conjugates market. The Centers for
Disease Control (CDC) has mentioned that vaccination has proven as the best
medium towards the prevention of diseases and has reduced the impact of various
life-threatening diseases.
On the other hand, Europe’s vaccine conjugates market is highly
driven by extensive research and development activities in the fields of
biotechnology and vaccine conjugates within various countries in the region.
The vaccine conjugates market in the region is expected to register faster
growth and is anticipated to follow the Americas. Owing to the rising demand
for genetically modified organisms, the market in Europe is showcasing huge
growth potential during the forecast period.
Asia Pacific is anticipated to grow at a steady rate for vaccine
conjugates during the forecast period. This can be owed to a growing prevalence
of geriatric population and the prevalence of infectious diseases. Countries
such as Singapore, India, China, and Japan are projected to showcase
extraordinary growth opportunities for vaccine conjugate providers during the
forthcoming years. Medical institutes in Asia Pacific are primarily focusing on
the use of vaccine conjugates and numerous research and development activities
over for the same.
Key Players
The report by MRFR on global vaccine conjugates market has
mentioned many prominent players in the market including GlaxoSmithKline plc
(U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi Pasteur SA
(France), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson
& Johnson (U.S.), Medimmune, LLC (U.S.), Astellas Pharma Inc. (Japan),
Serum Institute of India (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe
Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Fablife.
(India), SutroVax Inc. (U.S), and Sinovac Biotech Ltd. (China).
Industry Update
June 2019: Novavax has entered into a strategic partnership with
Catalent Biologics to expand their gene therapy footprint. Novavax is a
biotechnology company that develops next-generation vaccines for serious
infectious diseases. Catalent Biologics develops and manufactures gene
therapies as well as antibody-drug conjugates.
About
Market Research Future:
At Market
Research Future (MRFR),
we enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR),
Statistical Report, Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact
Us:
Market
Research Future
Hadapsar,
Pune – 411028
Maharashtra,
India
Phone: +1 646 845 9312
